Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present)

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clinicians. 2018;68(6):342–394.
   Web of Science ®Google Scholar
• Jordan CV. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213.
   PubMed Web of Science ®Google Scholar
• Quirke VM. Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine. Front Pharmacol. 2017;8:620.
   PubMed Web of Science ®Google Scholar
• Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther. 2002;24:A3–A16.
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846.
   PubMed Web of Science ®Google Scholar
• Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endo Rel Can. 2000;7(1):17–28
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.
   PubMed Web of Science ®Google Scholar
• Willson TM, Henke BR, Momtahen TM, et al. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem. 1994;37(11):1550–1552.
   PubMed Web of Science ®Google Scholar
• Seragon Pharmaceuticals. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer. WO2015082990; 2015.
   Google Scholar
• Lai A, Kahraman M, Govek S, et al. Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J Med Chem. 2015;58(12):4888–4904.
   PubMed Web of Science ®Google Scholar
• Aragon Pharmaceuticals. Estrogen receptor modulators and uses thereof. WO2012037410; 2012.
   Google Scholar
• Aragon Pharmaceuticals. Estrogen receptor modulators and uses thereof. WO2012037411; 2012.
   Google Scholar
• Genentech Inc. Crystalline forms of an estrogen receptor modulator. WO2016023847; 2016.
   Google Scholar
• Genentech Inc. Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid. WO2017060326; 2017.
   Google Scholar
• Novartis AG. Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders. WO2014130310; 2014.
   Google Scholar
• Tria GS, Abrams T, Baird J, et al. Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer. J Med Chem. 2018;61(7):2837–2864.
   PubMed Web of Science ®Google Scholar
• Novartis AG. Pharmaceutical combination comprising LSZ102 and alpelisib. WO2019106604; 2019.
   Google Scholar
• Novartis AG. Pharmaceutical combination comprising LSZ102 and ribociclib. WO2019097426; 2019.
   Google Scholar
• Novartis AG. 1,2,3,4-Tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders, and their preparation. WO2015092634; 2015.
   Google Scholar
• Burks HE, Abrams T, Kirby CA, et al. Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERα+ breast cancer. J Med Chem. 2017;60(7):2790–2818.
   PubMed Web of Science ®Google Scholar
• The Board of Trustees of the University of Illinois. Benzothiophene-based selective estrogen receptor downregulators. WO2017100712; 2017.
   Google Scholar
• The Board of Trustees of the University of Illinois. Benzothiophene-based selective estrogen receptor downregulator compounds. WO2017100715; 2017.
   Google Scholar
• Xiong R, Zhao J, Gutgesell LM, et al. Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer. J Med Chem. 2017;60(4):1325–1342.
   PubMed Web of Science ®Google Scholar
• Lu Y, Gutgesell LM, Xiong R, et al. Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer. J Med Chem. 2019;62(24):11301–11323.
   PubMed Web of Science ®Google Scholar
• The Board of Trustees of the University of Illinois. Combination therapy for the treatment of cancer. WO2018129387; 2018.
   Google Scholar
• The Board of Trustees of the University of Illinois. Benzothiophene-based selective estrogen receptor downregulator compounds. WO2018081168; 2018.
   Google Scholar
• The Board of Trustees of the University of Illinois. Antiestrogens for cancer therapy. WO2018175965; 2018.
   Google Scholar
• Min J, Guillen VS, Sharma N, et al. Adamantyl antiestrogens with novel side chains reveal a spectrum of activities in suppressing estrogen receptor mediated activities in breast cancer cells. J Med Chem. 2017;60(14):6321–6336.
   PubMed Web of Science ®Google Scholar
• Wang L, Guillen VS, Sharma N, et al. New class of selective estrogen receptor degraders (SERDs): expanding the toolbox of protac degrons. ACS Med Chem Lett. 2018;9(8): 803–808.
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. Chemical compounds. WO2014191726; 2014.
   Google Scholar
• De Savi C, Bradbury RH, Rabow AA, et al. Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. J Med Chem. 2015;58(20):8128–8140.
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity. WO2017182495; 2017.
   Google Scholar
• Scott JS, Bailey A, Buttar D, et al. Tricyclic indazoles − A novel class of selective estrogen receptor degrader antagonists. J Med Chem. 2019;6(3):1593–1608.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Piperidine derivative and preparation method and pharmaceutical use thereof. WO2016202161; 2016.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Benzopiperidine derivative, preparation method thereof and medical use thereof. WO2017107754; 2017.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Use of SERD with CDK4/6 inhibitor and PI3k/mTOR pathway inhibitor. WO2018233620; 2018.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Salt of benzopiperidine derivative and crystal form thereof, and method for preparing salt and crystal form thereof WO2018233591; 2018.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Crystal form of L-lysinate of benzopiperidine derivative and preparation method thereof. CN111349076; 2020.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Application of combination of tyrosine kinase inhibitor, CDK4/6 inhibitor and SERD in preparation of drug for treating tumors CN111184863; 2020.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Acrylic acid derivative, preparation method therefore and medical application of acrylic acid derivative CN106518768; 2017.
   Google Scholar
• Kalyra Pharmaceuticals. Estrogen receptor modulators. WO2017172957; 2017.
   Google Scholar
• Recurium IP Holdings. Estrogen receptor modulators for treating mutants. WO2021026153; 2021.
   Google Scholar
• Recurium IP Holdings. Salts and forms of an estrogen receptor modulator. WO2021091819; 2021.
   Google Scholar
• Recurium IP Holdings. Combinations. WO2021127036; 2021.
   Google Scholar
• Recurium IP Holdings. Combinations. WO2021127042; 2021.
   Google Scholar
• Recurium IP Holdings. Combinations. WO2021127043; 2021.
   Google Scholar
• Recurium IP Holdings. Combinations. WO2021127046; 2021.
   Google Scholar
• Recurium IP Holdings. Combinations. WO2021127047; 2021.
   Google Scholar
• Zeno Royalties & Milestones. Acrylic acid analogs. WO2019023481; 2019.
   Google Scholar
• Zhejiang Hisun Pharmacetical Co. Acrylic acid derivative, preparation method and use in medicine thereof. WO2017080338; 2017.
   Google Scholar
• Zhejiang Hisun Pharmacetical Co. Crystal forms of acrylic acid derivatives, preparation method therefor and use thereof. WO2020238733; 2020.
   Google Scholar
• Zhejiang Hisun Pharmacetical Co. Acrylic acid-based derivative, preparation method thereof and medical use thereof. WO2018001232; 2018.
   Google Scholar
• Sichuan Kelun Botai Biological Medicine Co. 3-Substituted acrylic acid compound as well as preparation method and application thereof. CN107814798; 2018.
   Google Scholar
• Sichuan Kelun Botai Biological Medicine Co. Solid form of heterocyclic compound and production method thereof. CN109970734; 2018.
   Google Scholar
• Sichuan Kelun Botai Biological Medicine Co. Substituted alkene benzopyrazole compound, its preparation method and application. CN107973780; 2018.
   Google Scholar
• Nanjing Sanhome Pharmaceutical Co. Pentacyclic compound as selective estrogen receptor down-regulator and use thereof. WO2018130123; 2018.
   Google Scholar
• Nanjing Sanhome Pharmaceutical Co. Tricyclic compound as selective estrogen receptor down-regulator and use thereof. WO2018130124; 2018.
   Google Scholar
• Nanjing Sanhome Pharmaceutical Co. Tetracyclic compound serving as selective estrogen receptor regulating agent and application thereof. CN108864080; 2018.
   Google Scholar
• Zhang X, Wang Y, Li X, et al. Dynamics-based discovery of novel, potent benzoic acid derivatives as orally bioavailable selective estrogen receptor degraders for ERα+ breast cancer. J Med Chem. 2021;64(11):7575–7595.
   PubMed Web of Science ®Google Scholar
• Luoxin Biotechnology Co. Indolo-substituted-piperidine compounds as estrogen receptor degrading agent. WO2017162206; 2017.
   Google Scholar
• Luoxin Biotechnology Co. Crystal form of estrogen receptor inhibitor and preparation method therefor. WO2019057201; 2019.
   Google Scholar
• Luoxin Biotechnology Co. Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor. WO2020108154; 2020.
   Google Scholar
• Dong J, Wang T-L, Lu J, et al. Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD). Bioorg Med Chem Lett. 2020;30(22):127601.
   PubMed Web of Science ®Google Scholar
• Inventisbio Inc. Selective estrogen receptor degraders and uses thereof. WO2017136688; 2017.
   Google Scholar
• Inventisbio Co. Novel salts of selective estrogen receptor degraders. WO2020132785; 2020.
   Google Scholar
• Shanghai Xunhe Pharmaceutical Co. Tetrahydroisoquinoline compound used as selective estrogen receptor down-regulation agent, synthetic method and application. CN111825613; 2020.
   Google Scholar
• Xavier University of Louisiana. Selective estrogen receptor down-regulators (SERDs). WO2017192991; 2017.
   Google Scholar
• Liu J, Zheng S, Guo S, et al. Rational design of a Boron-Modified triphenylethylene (GLL398) as an oral selective estrogen receptor downregulator. ACS Med Chem Lett. 2017;8(1):102–106.
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng S, Akerstrom VL, et al. Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD). J Med Chem. 2016;59(17):8134–8140.
   PubMed Web of Science ®Google Scholar
• Blizzard TA. Selective estrogen receptor modulator medicinal chemistry at Merck. A review. Curr Top Med Chem. 2008;8(9):792–812.
   PubMed Web of Science ®Google Scholar
• Eisai Co. Selective estrogen receptor modulators. WO2004058682; 2004.
   Google Scholar
• Garner F, Shomali M, Paquin D, et al., RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 26(9): 948–956. 2015.
   PubMed Web of Science ®Google Scholar
• Radius Health. Methods of treating cancer using a combination of RAD1901 and palbociclib. WO2016176666; 2016.
   Google Scholar
• Radius Health. Methods for treating cancer. WO2016176664; 2016.
   Google Scholar
• Radius Health. Methods for treating ovarian cancer. WO201804231; 2018.
   Google Scholar
• Radius Pharmaceuticals. Elacestrant in combination with abemaciclib in women with breast cancer. WO2020112765; 2020.
   Google Scholar
• Radius Pharmaceuticals. Methods for treating cancer resistant to CDK4/6 inhibitors. WO2020118213; 2020.
   Google Scholar
• Radius Pharmaceuticals. Methods for treating cancer in models harboring ESR1 mutations. WO2020118202; 2020.
   Google Scholar
• Radius Pharmaceuticals. Polymorphic forms of RAD1901-2HCl and antitumor uses thereof. WO2018129419; 2018.
   Google Scholar
• Radius Pharmaceuticals. polymorphic forms of RAD1901-2HCl. WO2020010216; 2020.
   Google Scholar
• Radius Pharmaceuticals. Processes and compounds. WO2020167855; 2020.
   Google Scholar
• Radius Pharmaceuticals. Estrogen receptor-modulating compounds. WO2019144132; 2019.
   Google Scholar
• Radius Pharmaceuticals. Estrogen receptor-modulating compounds. WO2021016254; 2021.
   Google Scholar
• Seragon Pharmaceuticals. Estrogen receptor modulator and uses thereof. WO2014205138; 2014.
   Google Scholar
• Kahraman M, Govek SP, Nagasawa JY, et al. Maximizing ER-α degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927. ACS Med Chem Lett. 2018;10(1):50–55.
   PubMed Web of Science ®Google Scholar
• Genentech Inc. Therapeutic combinations with estrogen receptor modulators. WO2015136016; 2015.
   Google Scholar
• Genentech Inc. Methods and compositions for modulating estrogen receptor mutants. WO2015136017; 2015.
   Google Scholar
• Genentech Inc. Derivatives of 2,3-diphenylchromene useful for the treatment of cancer. WO2016097073; 2016.
   Google Scholar
• Genentech Inc. Heterocyclic estrogen receptor modulators and uses thereof. WO2016189011; 2016.
   Google Scholar
• Genentech Inc. Estrogen receptor modulators and uses thereof. WO2016097071; 2016.
   Google Scholar
• Genentech Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof. WO2016097072; 2016.
   Google Scholar
• Liang J, Zbieg JR, Blake RA, et al., GDC-9545 (Giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for er+ breast cancer. J Med Chem. 64(16): 11841–11856. 2021.
   PubMed Web of Science ®Google Scholar
• Genentech Inc. Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use. WO2019245974; 2019.
   Google Scholar
• Genentech Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof. WO2017216280; 2017.
   Google Scholar
• Genentech Inc. Heteroaryl estrogen receptor modulators and uses thereof. WO2017216279; 2017.
   Google Scholar
• Genentech Inc. Tetrahydronaphthalene estrogen receptor modulators and uses thereof. WO2017080966; 2017.
   Google Scholar
• Genentech Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof. WO2017174757; 2017.
   Google Scholar
• AstraZeneca AB. Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer. WO2017182493; 2017.
   Google Scholar
• AstraZeneca AB. 6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer. WO2018077630; 2018.
   Google Scholar
• Scott JS, Moss TA, Balazs A, et al., Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist. J Med Chem. 63(23): 14530–14559. 2020.
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. Chemical compounds. WO2019002441; 2019.
   Google Scholar
• AstraZeneca AB. Chemical compounds. WO2019002442; 2019.
   Google Scholar
• AstraZeneca AB. N-(2-(4-((1R,3R)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer. WO2018019793; 2018.
   Google Scholar
• AstraZeneca AB. Estrogen receptor modulators. WO2018138303; 2018.
   Google Scholar
• Sanofi. Preparation of substituted 6,7-dihydro-5h-benzo[7]annulene compounds, and therapeutic uses thereof. WO2017140669; 2017.
   Google Scholar
• El-Ahmad Y, Tabart M, Halley F, et al. DiScovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective EStrogen Receptor Degrader (SERD) for the Treatment of EStrogen-Receptor-PoSitive BreaSt Cancer. J Med Chem. 63(2): 512–528. 2020.
   PubMed Web of Science ®Google Scholar
• Sanofi. Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof. WO2018091153; 2018.
   Google Scholar
• Sanofi. Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for treatment of cancer including breast cancer. WO2019020559; 2019.
   Google Scholar
• Sanofi. Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof. WO2020049150; 2020.
   Google Scholar
• Sanofi. Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate. WO2020049153; 2020.
   Google Scholar
• Sanofi. 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients. WO2020225375; 2020.
   Google Scholar
• Sanofi. Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative. WO2021116074; 2021.
   Google Scholar
• Sanofi. Preparation of novel substituted 6,7-dihydro-5H-benzo[7]annulene compounds as inhibitors and degraders of estrogen receptors. WO2021063967; 2021.
   Google Scholar
• Eli Lilly & Co. Selective estrogen receptor degraders. WO2020014440; 2020.
   Google Scholar
• Eli Lilly & Co. Selective estrogen receptor degraders. WO2020014435; 2020.
   Google Scholar
• Olema pharmaceuticals. Combinations of benzopyran compounds, compositions and uses thereof. WO2014203129; 2014.
   Google Scholar
• Sw F, Hodges-Gallagher L, Dc M, et al. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun. 2018;9:2368.
   PubMed Web of Science ®Google Scholar
• Pfizer. Anti-estrogenic compounds. WO2016174551; 2016.
   Google Scholar
• Olema pharmaceuticals. Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs. WO2017059139; 2017.
   Google Scholar
• Olema pharmaceuticals. Regimens of estrogen receptor antagonists. WO2021007146; 2021.
   Google Scholar
• G1 Therapeutics Inc. Benzothiophene estrogen receptor modulators. WO2018148576; 2018.
   Google Scholar
• The Board of Trustees of the University of Illinois. Substituted benzothiophene analogs as selective estrogen receptor degraders. WO2019157020; 2019.
   Google Scholar
• G1 Therapeutics Inc. Benzothiophene estrogen receptor modulators to treat medical disorders. WO2020037251; 2020.
   Google Scholar
• Sun Pharma Advanced Research Co. Novel N-aryl containing fused heterocyclic compounds. WO2017056115; 2017.
   Google Scholar
• Sun Pharma Advanced Research Co. Novel antiestrogenic heterocyclic compounds. WO2018138739; 2018.
   Google Scholar
• Sun Pharma Advanced Research Co. Novel heterocyclic antiestrogens. WO2017072792; 2017.
   Google Scholar
• Sun Pharma Advanced Research Co. Selective estrogen receptor degrader WO2021014386; 2021.
   Google Scholar
• Dizal Pharmaceutical Co. Selective estrogen receptor downregulators and uses thereof. WO2019228443; 2019.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Tetrahydroisoquinoline derivative, and preparation method and medical application thereof. CN111499614; 2020.
   Google Scholar
• Anlin Pharmaceutical Co. Heterocyclic compound and application thereof in medicine. WO2019096106; 2019.
   Google Scholar
• Shenzhen Forward Pharmaceutical Co. Estrogen receptor degrading agent for treating breast cancer. WO2019192533; 2019.
   Google Scholar
• Luoxin Biotechnology Co. Indolo substituted piperidine compound as estrogen receptor degrading agent. WO2018077260; 2018.
   Google Scholar
• Furman C, Hao M-H, Prajapati S, et al. Estrogen receptor covalent antagonists: the best is yet to come. Cancer Res. 2019;79(8):1740–1745.
   PubMed Web of Science ®Google Scholar
• Eisai R&D Management Co. Tetrasubstituted alkene compounds and their use. WO2016196342; 2016.
   Google Scholar
• Eisai R&D Management Co. Tetrasubstituted alkene compounds and their use. WO2016196346; 2016.
   Google Scholar
• Eisai R&D Management Co. Tetrasubstituted alkene compounds and their use. WO2016196337; 2016.
   Google Scholar
• Puyang X, Furman C, Zheng GZ, et al., Discovery of selective estrogen receptor covalent antagonists for the treatment Of ERαWT and ERαMUT breast cancer. Cancer Discov. 8(9): 1176–1193. 2018.
   PubMed Web of Science ®Google Scholar
• Rioux N, Smith S, Korpal M, et al. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019;83(1):151–160.
   PubMed Web of Science ®Google Scholar
• Eisai R&D Management Co. combination therapies for the treatment of breast cancer. WO2018170447; 2018.
   Google Scholar
• Eisai R&D Management Co. A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor. WO2020242795; 2020.
   Google Scholar
• Eisai R&D Management Co. Salts of indazole derivative and crystals thereof. WO2019225552; 2019.
   Google Scholar
• Eisai R&D Management Co. Tetrasubstituted alkene compounds and their use for the treatment of breast cancer. WO2018098305; 2018.
   Google Scholar
• Eisai R&D Management Co. Tetrasubstituted alkene compounds and their use. WO2018098251; 2018.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Benzopiperidine or heteroarylpiperidine derivative, preparation method therefor, and medical application thereof. WO2019223715; 2019.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Preparation of pharmaceutically acceptable salts of benzopiperidine derivative. CN112830919; 2021.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Indazole derivative, preparation method therefor, and pharmaceutical application thereof. WO2020253762; 2020.
   Google Scholar
• Xavier University of Louisiana. Estrogen receptor targeting antagonists. WO2020055973; 2020.
   Google Scholar
• Medshine Discovery Inc. Estrogen receptor antagonist. WO2020125640; 2020.
   Google Scholar
• Wuhan University. Oxygen bridged bicycloheptene sulfonamide compound containing different alkyl chain length useful in treatment of breast cancer and its preparation. CN108794519; 2018.
   Google Scholar
• Hu Z, Li Y, Xie B, et al. Novel class of 7-oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity. E J Med Chem. 2019; 182: 111605.
   PubMed Web of Science ®Google Scholar
• Wuhan University. Preparation of oxygen-bridged bicyclo-[2.2.1]-heptene compounds for treatment of breast cancer. CN109942595; 2019.
   Google Scholar
• Li Y, Zhang S, Zhang J, et al. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs). E J Med Chem. 2019; 172: 48–61.
   PubMed Web of Science ®Google Scholar
• Wuhan University. Preparation of oxygen bridged diheptene sulfonamide compounds for treating breast cancer. CN107056799; 2017.
   Google Scholar